| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.15.22 |
| P698 | PubMed publication ID | 25952786 |
| P50 | author | Marco Redaelli | Q40357396 |
| Antonio Caretta | Q42357025 | ||
| P2093 | author name string | Carla Mucignat-Caretta | |
| Enrico Giordan | |||
| Maira Zorzan | |||
| P2860 | cites work | VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex | Q24293027 |
| PML regulates p53 stability by sequestering Mdm2 to the nucleolus | Q24296743 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA | Q24550956 | ||
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Q24605258 | ||
| Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists | Q24632161 | ||
| Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma | Q24644727 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges | Q26862516 | ||
| PTEN modulators: a patent review | Q26995513 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
| Glioma stem cells promote radioresistance by preferential activation of the DNA damage response | Q27860541 | ||
| Oncomirs - microRNAs with a role in cancer | Q27860773 | ||
| Hedgehog signaling in animal development: paradigms and principles | Q28208463 | ||
| Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells | Q39352627 | ||
| Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models | Q39421577 | ||
| Transcriptional and post-transcriptional down-regulation of cyclin D1 contributes to C6 glioma cell differentiation induced by forskolin | Q39561050 | ||
| Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status | Q39756064 | ||
| Selective distribution of protein kinase A regulatory subunit RII{alpha} in rodent gliomas. | Q39949940 | ||
| Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway | Q39992451 | ||
| CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). | Q40091567 | ||
| Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies | Q40105658 | ||
| MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma | Q40293483 | ||
| Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
| Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation | Q40444094 | ||
| SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo | Q40497236 | ||
| Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. | Q40707342 | ||
| The new WHO classification of brain tumours | Q40807273 | ||
| Transcriptional repression by the promyelocytic leukemia protein, PML. | Q41071228 | ||
| Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells | Q41333283 | ||
| Acetate is a bioenergetic substrate for human glioblastoma and brain metastases | Q41667697 | ||
| Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice | Q42041511 | ||
| Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab | Q42058928 | ||
| On the origin of glioma | Q42140302 | ||
| PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells | Q42148487 | ||
| Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment | Q43269529 | ||
| Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide | Q43290402 | ||
| Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. | Q43542232 | ||
| Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer | Q44656784 | ||
| Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence | Q37976901 | ||
| Epidermal growth factor receptor: a re-emerging target in glioblastoma | Q38046057 | ||
| Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting | Q38051894 | ||
| TGF-β as a therapeutic target in high grade gliomas - promises and challenges. | Q38060439 | ||
| Epidermal growth factor receptor as a therapeutic target in glioblastoma | Q38098098 | ||
| Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. | Q38610488 | ||
| Integrin control of the transforming growth factor-β pathway in glioblastoma. | Q39200138 | ||
| Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway | Q39248972 | ||
| Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro | Q28219465 | ||
| Escaping from the TGFbeta anti-proliferative control | Q28240031 | ||
| Extensive modulation of a set of microRNAs in primary glioblastoma | Q28263314 | ||
| TGFbeta in Cancer | Q28288866 | ||
| Cancer stem cells in solid tumours: accumulating evidence and unresolved questions | Q28293535 | ||
| PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration | Q28378001 | ||
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | Q28472048 | ||
| Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 | Q28487568 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function | Q29547320 | ||
| Notch signalling: a simple pathway becomes complex | Q29555851 | ||
| MicroRNAs in Cancer | Q29615539 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| microRNA-34a is tumor suppressive in brain tumors and glioma stem cells | Q30428366 | ||
| Noninvasive and real-time assessment of reconstructed functional human endometrium in NOD/SCID/gamma c(null) immunodeficient mice | Q30478957 | ||
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | Q30661157 | ||
| Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations | Q30885944 | ||
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence | Q31148416 | ||
| Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma | Q33399939 | ||
| A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma | Q33402531 | ||
| Continuous daily sunitinib for recurrent glioblastoma | Q33403947 | ||
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial | Q33417361 | ||
| Protein kinase A regulatory subunit distribution in medulloblastoma | Q33557542 | ||
| Expression of the neural RNA-binding protein Musashi1 in human gliomas | Q33941154 | ||
| Molecular events implicated in brain tumor angiogenesis and invasion | Q34056893 | ||
| Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma | Q34113523 | ||
| Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients | Q34117487 | ||
| Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape | Q34136498 | ||
| A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) | Q34269566 | ||
| Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study | Q34480536 | ||
| Retracted: The Different Role of Notch1 and Notch2 in Astrocytic Gliomas | Q34562277 | ||
| Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion | Q34606869 | ||
| Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma | Q34621127 | ||
| Standard Therapy for Glioblastoma- A Review of Where We Are | Q34623983 | ||
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma | Q34722415 | ||
| Genetic pathways to glioblastoma: a population-based study | Q44673208 | ||
| Overexpression of RII beta regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RII beta | Q45219732 | ||
| Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo | Q45855175 | ||
| Smoothing out drug resistance. | Q45913939 | ||
| A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. | Q45981742 | ||
| Expression of the Neural RNA-binding protein Musashi1 in pediatric brain tumors | Q48107261 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma | Q48810234 | ||
| Molecular pathology and clinical characteristics of oligodendroglial neoplasms | Q48874973 | ||
| Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. | Q54626874 | ||
| PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. | Q54651230 | ||
| AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. | Q55463295 | ||
| Protein kinase A regulatory subunits in colon cancer | Q34786124 | ||
| Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation | Q34966234 | ||
| Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption | Q34997337 | ||
| Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma | Q35008709 | ||
| The role of transforming growth factor-beta in primary brain tumors | Q35011399 | ||
| Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. | Q35042985 | ||
| Drugging the PI3 kinome: from chemical tools to drugs in the clinic. | Q35622141 | ||
| HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity | Q35757997 | ||
| Current trends in targeted therapies for glioblastoma multiforme | Q35864226 | ||
| Hedgehog pathway as a drug target: Smoothened inhibitors in development | Q35885181 | ||
| Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway. | Q35925314 | ||
| Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors | Q35967385 | ||
| Identification of a tumour suppressor network opposing nuclear Akt function | Q35991130 | ||
| Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. | Q36212896 | ||
| D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function | Q36240913 | ||
| A phase I/II trial of vandetanib for patients with recurrent malignant glioma | Q36401846 | ||
| Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited | Q36428702 | ||
| Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. | Q36511945 | ||
| MicroRNA expression and function in cancer | Q36637333 | ||
| PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies | Q36693019 | ||
| A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas | Q36792681 | ||
| Molecular pathology of malignant gliomas | Q37014747 | ||
| Interaction of PACAP with Sonic hedgehog reveals complex regulation of the hedgehog pathway by PKA. | Q37158885 | ||
| Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain | Q37308322 | ||
| EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. | Q37445712 | ||
| Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines | Q37455274 | ||
| Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. | Q37593483 | ||
| Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells | Q37599450 | ||
| Targeting Notch to target cancer stem cells. | Q37763414 | ||
| Targeting mTOR in cancer: renal cell is just a beginning | Q37766475 | ||
| Cancer-associated IDH mutations: biomarker and therapeutic opportunities | Q37802750 | ||
| The Notch signaling pathway: molecular basis of cell context dependency | Q37815315 | ||
| Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments | Q37891886 | ||
| Current concepts and management of glioblastoma | Q37904921 | ||
| MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas | Q37917655 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1407-1420 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Molecular targets in glioblastoma | |
| P478 | volume | 11 |
| Q33567030 | Advances in epigenetic glioblastoma therapy |
| Q91829128 | Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study |
| Q64079304 | EGFLAM correlates with cell proliferation, migration, invasion and poor prognosis in glioblastoma |
| Q52321920 | Efficient gene silencing in brain tumors with hydrophobically modified siRNAs. |
| Q61446856 | Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells |
| Q58748866 | Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway |
| Q93073730 | Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas |
| Q92835893 | Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma |
| Q64070787 | NAMPT as a Dedifferentiation-Inducer Gene: NAD as Core Axis for Glioma Cancer Stem-Like Cells Maintenance |
| Q47265360 | Protein Kinase A Distribution Differentiates Human Glioblastoma from Brain Tissue |
| Q37736085 | Quantum Dots-siRNA Nanoplexes for Gene Silencing in Central Nervous System Tumor Cells |
| Q38541950 | RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies |
| Q92354517 | The total flavonoid of Eucommia ulmoides sensitizes human glioblastoma cells to radiotherapy via HIF-α/MMP-2 pathway and activates intrinsic apoptosis pathway |
Search more.